MedPath

A placebo controlled study on the effect of oxandrolone in combination with authentic biosynthetic human growth hormone and low-dose oestrogens on growth and metabolic parameters in girls with Turner's syndrome.

Completed
Conditions
girls with Turner syndrome
Registration Number
NL-OMON23518
Lead Sponsor
Pfizer (New York), previously Pharmacia; and Lilly (Indianapolis, USA)
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
135
Inclusion Criteria

Turner syndrome, confirmed by chromosomal analysis. 3 age ranges: 2.00-7.99 yrs, 8-11.99 yrs, 12.00-15.99 yrs.

Exclusion Criteria

1. Any other disorder that may affect growth;

2. Hydrocephalus;
3. Other experimental drug study;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Final height.
Secondary Outcome Measures
NameTimeMethod
Potential side effects (glucose intolerance; lowering of the voice); <br />psychosexual changes.
© Copyright 2025. All Rights Reserved by MedPath